刘晓妍,杨帆,龚艳君

• 1:北京大学第一医院心内科

摘要(Abstract)：

<正>11-脱氢血栓素B_2(11-dehydro-thromboxane B_2,11dh TXB_2)是血栓烷素A2(thromboxane A2,TX_A2)的终末代谢产物,主要经肾排出。TXA_2则是花生四烯酸在环氧合酶(cyclooxygenase,COX)作用下产生的具有促血小板聚集、收缩血管等生物活性作用的物质,在血栓形成过程中有重要作用。阿司匹林能通过不可逆地抑制COX-1活性,减少TXA_2合成,从而抑制血小板聚集及其在冠状动脉粥样硬化性心脏病(冠心病)发展和急性冠状动脉综合征(acute coronary syndrome,ACS)发生中的作用。TXA_2的代谢产

关键词(KeyWords)： 血栓烷素11-脱氢血栓素B2;血小板高反应性;阿司匹林抵抗;冠状动脉粥样硬化性心脏病

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 刘晓妍,杨帆,龚艳君

参考文献(References)：

• [1]Fitz Gerald GA,Healy C,Daugherty J.Thromboxane A2biosynthesis in human disease.Fed Proc,1987,46(1):154-158.
• [2]Patrono C,García Rodríguez LA,Landolfi R,et al.Low-dose aspirin for the prevention of atherothrombosis.N Engl J Med,2005,353(353):2373-2383.
• [3]Patrono C,Coller B,Fitz Gerald GA,et al.Platelet-active drugs:the relationships among dose,effectiveness,and side effects:the seventh ACCP conference on antithrombotic and thrombolytic therapy.Chest,2004,126(3 Suppl):234S-264S.
• [4]Rocca B,Secchiero P,Ciabattoni G,et al.Cyclooxygenase-2expression is induced during human megakaryopoiesis and characterizes newly formed platelets.Proc Nati Acad Sci U S A,2002,99(11):7634-7639.
• [5]Lopez LR,Guyer KE,Torre IG,et al.Platelet thromboxane(11-dehydro-Thromboxane B2)and aspirin response in patients with diabetes and coronary artery disease.World J Diabetes,2014,5(2):115-127.
• [6]Catella F,Healy D,Lawson JA,et al.11-Dehydrothromboxane B2:a quantitative index of thromboxane A2 formation in the human circulation.Proc Natl Acad Sci U S A,1986,83(16):5861-5865.
• [7]Renda G,De Caterina R.Measurements of thromboxane production and their clinical signifi cance in coronary heart disease.Thromb Haemost,2012,108(1):6-8.
• [8]Ciabattoni G,Pugliese F,Davi G,et al.Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man.Biochim Biophys Acta,1989,992(1):66-70.
• [9]De Filippis AP,Oloyede OS,Andrikopoulou E,et al.Thromboxane A(2)generation,in the absence of platelet COX-1 activity,in patients with and without atherothrombotic myocardial infarction.Circ J,2013,77(11):2786-2792.
• [10]Hansson GK.Infl ammation,atherosclerosis,and coronary artery disease.N Engl J Med,2005,352(16):1685-1695.
• [11]Ruggeri ZM.Platelets in atherothrombosis.Nat Med,2002,8(11):1227-1234.
• [12]Roth GJ,Stanford N,Majerus PW.Acetylation of prostaglandin synthase by aspirin.Proc Natl Acad Sci U S A,1975,72(8):3073-3076.
• [13]Pettersen AA,Arnesen H,Seljefl ot I.A brief review on high on-aspirin residual platelet reactivity.Vascul Pharmacol,2015,67-69:6-9.
• [14]Patrignani P,Filabozzi P,Patrono C.Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.J Clin Invest,1982,69(6):1366-1372.
• [15]Antithrombotic Trialists’Collaboration.Collaborative metaanalysis of randomised trials of antiplatelet therapy f or prevention of death,myocardial infarction,and stroke in high risk patients.BMJ,2002,324(7329):71-86.
• [16]Krasopoulos G,Brister SJ,Beattie WS,et al.Aspirin“resistance”and risk of cardiovascular morbidity:systematic review and meta-analysis.BMJ,2008,336(7637):195-198.
• [17]Christensen KH,Grove EL,Würtz M,et al.Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes.Platelets,2015,26(3):230-235.
• [18]Grove EL,Hvas AM,Mortensen SB,et al.Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease.J Thromb Haemost,2011,9(1):185-191.
• [19]Faraday N,Yanek LR,Vaidya D,et al.Leukocyte count is associated with increased platelet reactivity and diminished response to aspirin in healthy individuals with a family history of coronary artery disease.Thromb Res,2009,124(3):311-317.
• [20]Davi G,Patrono C.Platelet activation and atherothrombosis.N Engl J Med,2007,357(24):2482-2494.
• [21]Morrow JD,Hill KE,Burk RF,et al.A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase,f ree radical-catalyzed mechanism.Proc Natl Acad Sci U S A,1990,87(23):9383-9387.
• [22]G a o F,Wa n g Z X,M e n J L,e t a l.E f f e c t of polymorphism and typeⅡdiabetes on aspirin resistance in patients with unstable coronary artery disease.Chin Med J(Engl),2011,124(11):1731-1734.
• [23]O’Donnell CJ,Larson MG,Feng D,et al.Genetic and environmental contributions to platelet aggregation:the Framingham heart study.Circulation,2001,103(25):3051-3056.
• [24]Renda G,Tacconelli S,Capone ML,et al.Celecoxib,ibuprofen,and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease.Clin Pharmacol Ther,2006,80(3):264-274.
• [25]Chakroun T,Addad F,Abderazek F,et al.Screening for aspirin resistance in stable coronary artery patients by three different tests.Thromb Res,2007,121(3):413-418.
• [26]LordkipanidzéM,Pharand C,Schampaert E,et al.A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease.Eur Heart J,2007,28(14):1702-1708.
• [27]Liu T,Zhang J,Chen X,et al.Comparison between urinary 11-dehydrothromboxane B2 detection and platelet Light Transmission Aggregometry(LTA)assays for evaluating aspirin response in elderly patients with coronary artery disease.Gene,2015,571(1):23-27.
• [28]Olson MT,Kickler TS,Lawson JA,et al.Eff ect of assay specifi city on the association of urine 11-dehydro thromboxane B2 determination with cardiovascular risk.J Thromb Haemost,2012,10(12):2462-2469.
• [29]Eikelboom JW,Hirsh J,Weitz JI,et al.Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction,stroke,or cardiovascular death in patients at high risk for cardiovascular events.Circulation,2002,105(14):1650-1655.[3 0]Eikelboom JW,Hankey GJ,Thom F,et al.Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid:determinants and effect on cardiovascular risk.Circulation,2008,118(17):1705-1712.
• [31]Ames PR,Batuca JR,Muncy IJ,et al.Aspirin insensitive thromboxane generation is associated with oxidative stress in type 2 diabetes mellitus.Thromb Res,2012,130(3):350-354.
• [32]Vaidya D,Yanek LR,Faraday N,et al.Native platelet aggregation and response to aspirin in persons with the metabolic syndrome and its components.Metab Syndr Relat Disord,2009,7(4):289-296.
• [33]Vasudevan A,Bottiglieri T,Tecson KM,et al.Residual thromboxane activity and oxidative stress:infl uence on mortality in patients with stable coronary artery disease.Coron Artery Dis,2017,28(4):287-293.
• [34]Santilli F,Paloscia L,Liani R,et al.Circulating myeloidrelated protein-8/14 is related to thromboxane-dependent platelet activation in patients with acute coronary syndrome,with and without ongoing low-dose aspirin treatment.J Am Heart Assoc,2014,3(4).pii:e000903.
• [35]Maga P,Sanak M,Jawien J,et al.11-dehydro thromboxane B2 levels after percutaneous transluminal angioplasty in patients with peripheral arterial occlusive disease during a one year follow-up period.J Physiol Pharmacol,2016,67(3):377-383.
• [36]Gremmel T,Steiner S,Seidinger D,et al.Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation.Platelets,2011,22(3):188-195.
• [37]Bordeaux BC,Qayyum R,Yanek LR,et al.Eff ect of obesity on platelet reactivity and response to low-dose aspirin.Prev Cardiol,2010,13(2):56-62.
• [38]Dharmasaroja PA,Sae-Lim S.Effects of different doses,enteric-coated preparation of aspirin,and sex on urinary11-dehydrothromboxane B2 in healthy volunteers.Blood Coagul Fibrinolysis,2010,21(7):649-652.
• [39]Goncalves LH,Dusse LM,Fernandes AP,et al.Urinary11-dehydro thromboxane B2 levels in type 2 diabetic patients before and during aspirin intake.Clin Chim Acta,2011,412(15-16):1366-1370.
• [40]Chaudhary R,Bliden KP,Tantry US,et al.Association of weight gain with coronary artery disease,inflammation and thrombogenicity.J Thromb Thrombolysis,2016,41(3):394-403.
• [41]Varnell CD Jr,Goldstein SL,Yee DL,et al.Age-related differences in urinary 11-dehydroxythromboxane B2 between inf ants,children,and adolescents:another example of developmental hemostasis?Pediatr Blood Cancer,2014,61(11):2074-2076.
• [42]Ross S,Eikelboom J,Anand SS,et al.Association of cyclooxygenase-2 genetic variant with cardiovascular disease.Eur Heart J,2014,35(33):2242a-2248a.
• [43]Wang Z,Gao F,Men J,et al.Polymorphisms and high onaspirin platelet reactivity after off-pump coronary artery bypass grafting.Scand Cardiovasc J,2013,47(4):194-199.
• [44]Lemkes BA,Bahler L,Kamphuisen PW,et al.The infl uence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus.J Thromb Haemost,2012,10(4):639-646.
• [45]曲云霄,蒋知新,王丽丽,等.尿11-脱氢-血栓素B2对2型糖尿病患者冠状动脉病变的诊断价值研究.中国全科医学,2016,19(17):2094-2098.
• [46]曲云霄,蒋知新,韩腾龙,等.血小板参数及活化标志物与2型糖尿病患者颈动脉内膜中层厚度的相关性.实用医学杂志,2016,32(8):1250-1253.
• [47]DavìG,Gresele P,Violi F,et al.Diabetes mellitus,hypercholesterolemia,and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo.Evidence derived from the study of peripheral arterial disease.Circulation,1997,96(1):69-75.
• [48]Thomson VS,John B,George P,et al.Aspirin resistance in Indian patients with coronary artery disease and cardiovascular events.J Postgrad Med,2009,55(4):252-256.
• [49]Mc Cullough PA,Vasudevan A,Sathyamoorthy M,et al.Urinary 11-dehydro-thromboxane B2 and mortality in patients with stable coronary artery disease.Am J Cardiol,2017,119(7):972-977.
• [50]Matsuura E,Guyer K,Yamamoto H,et al.On aspirin treatment but not baseline thromboxane B2 levels predict adverse outcomes in patients with acute coronary syndromes.J Thromb Haemost,2012,10(9):1949-1951.
• [51]Bednar F,Osmancik P,Hlavicka J,et al.Aspirin is insuffi cient in inhibition of platelet aggregation and thromboxane formation early after coronary artery bypass surgery.J Thromb Thrombolysis,2009,27(4):394-399.
• [52]Wang Z,Gao F,Men F,et al.Aspirin resistance in off-pump coronary artery bypass grafting.Eur J Cardiothorac Surg,2012,41(1):108-112.
• [53]Addad F,Chakroun T,Abderazek F,et al.Response variability to aspirin and one-year prediction of vascular events in patients with stable coronary artery disease.J Thromb Thrombolysis,2010,29(1):108-113.
• [54]Szczeklik W,Stodó?kiewicz E,Rzeszutko M,et al.Urinary11-dehydro-thromboxane B2 as a predictor of acute myocardial infarction outcomes:results of leukotrienes and thromboxane in myocardial infarction(LTIMI)study.J Am Heart Assoc,2016,5(8).
• [55]Kakouros N,Nazarian SM,Stadler PB,et al.Risk factors for nonplatelet thromboxane generation after coronary artery bypass graf t surgery.J Am Heart Assoc,2016,5(3):e002615.
• [56]Karon BS,Wockenfus A,Scott R,et al.Aspirin responsiveness in healthy volunteers measured with multiple assay platforms.Clin Chem,2008,54(6):1060-1065.
• [57]Rosiak M,Postula M,Kap?on-Cie?licka A,et al.The effect of doubling the dose of acetylsalicylic acid(ASA)on platelet f unction parameters in patients with type 2 diabetes and platelet hyperreactivity during treatment with 75 mg of ASA:a subanalysis of the AVOCADO study.Kardiol Pol,2013,71(6):552-557.
• [58]Spectre G,Arnetz L,?stenson CG,et al.Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro-or macrovascular complications.Thromb Haemost,2011,106(3):491-499.
• [59]Hart RG,Leonard AD,Talbert RL,et al.Aspirin dosage and thromboxane synthesis in patients with vascular disease.Pharmacotherapy,2003,23(5):579-584.
• [60]Gurbel PA,Bliden KP,Di Chiara J,et al.Evaluation of doserelated effects of aspirin on platelet function:results from the Aspirin-Induced Platelet Effect(ASPECT)study.Circulation,2007,115(25):3156-3164.
• [61]Gasparovic H,Petricevic M,Kopjar T,et al.Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting.Am J Cardiol,2014,113(10):1660-1667.
• [62]Russo I,Traversa M,Bonomo K,et al.In central obesity,weight loss restores platelet sensitivity to nitric oxide and prostacyclin.Obesity(Silver Spring),2010,18(4):788-797.
• [63]Santilli F,Vazzana N,Iodice P,et al.Effects of high-amounthigh-intensity exercise on in vivo platelet activation:modulation by lipid peroxidation and AGE/RAGE axis.Thromb Haemost,2013,110(6):1232-1240.
• [64]Bliden KP,Singla A,Gesheff MG,et al.Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin.Thromb Haemost,2014,112(2):323-331.
• [65]Goncalves LH,Silva MV,Duarte RC,et al.Acetylsalicylic acid therapy:infl uence of metformin use and other variables on urinary 11-dehydrothromboxane B2 levels.Clin Chim Acta,2014,429:76-78.
• [66]Alusik S,Paluch Z,LejskováM,et al.The inhibitory effect of statins on urinary 11-dehydrothromboxane levels.Int Angiol,2010,29(3):255-259.
• [67]Véricel E,Colas R,Calzada C,et al.Moderate oral supplementation with docosahexaenoic acid improves platelet function and oxidative stress in type 2 diabetic patients.Thromb Haemost,2015,114(2):289-296.
• [68]Santilli F,Rocca B,De Cristof aro R,et al.Platelet cyclooxygenase inhibition by low-dose aspirin is not refl ected consistently by platelet function assays:implications for aspirin“resistance”.J Am Coll Cardiol,2009,53(8):667-677.
• [69]Kap?on-Cie?licka A,Rosiak M,Postula M,et al.Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes.Kardiol Pol,2013,71(9):893-902.